Back to research

Research paper

Treatment of electrical status epilepticus in sleep: A pooled analysis of 575 cases

Landmark pooled analysis of 575 ESES cases. Response rates: surgery ~90%, corticosteroids ~81%, benzodiazepines ~68%, sulthiame ~53%, levetiracetam ~54%, standard ASMs ~49%. Oxcarbazepine and carbamazepine can worsen spike-wave index and should be avoided.

Indexed context

van den Munckhof B, et al.

esesdee-swastreatmentcorticosteroidspooled-analysis

Markdown path

content/research/papers/2015-van-den-munckhof-eses-pooled-analysis-575.md

Findings

Landmark pooled analysis of 575 ESES cases. Response rates: surgery ~90%, corticosteroids ~81%, benzodiazepines ~68%, sulthiame ~53%, levetiracetam ~54%, standard ASMs ~49%. Oxcarbazepine and carbamazepine can worsen spike-wave index and should be avoided.

Why it may matter for Levi

Primary-source underpinning for Levi's treatment hierarchy, previously cited via the Kotagal 2017 review. Quantitatively supports the March 2026 IV methylprednisolone pulse-first strategy (81% response). The avoid-oxcarbazepine/carbamazepine signal should be confirmed communicated to Stanford and UCSF epileptology. Response rates are for initial response, not durability.

Paper text

van den Munckhof et al. (2015) — Pooled analysis of 575 ESES cases

Source

Why this paper is in the corpus

The landmark pooled analysis of ESES treatment efficacy that became the primary quantitative reference for ranking first-line therapies. Often cited as the definitive evidence that standard ASMs alone are inadequate in DEE-SWAS and that steroids, benzodiazepines, and surgery are superior. The Kotagal 2017 review already in the corpus cites this paper; adding it directly preserves a primary-source link.

Key findings

  • Pooled analysis of 575 cases across published series.
  • Response rates reported for improvement in cognition and/or EEG:
    • Surgery ~90%
    • Corticosteroids ~81%
    • High-dose benzodiazepines ~68%
    • Sulthiame ~53%
    • Levetiracetam ~54%
    • Standard antiseizure medications (ASMs) combined ~49%.
  • Oxcarbazepine and carbamazepine can worsen spike-wave index and should be avoided.
  • Establishes that ASM-only treatment is insufficient for the primary goal of suppressing sleep-activated spike-wave to prevent or reverse cognitive regression.

Levi-relevant takeaways

  • Primary-source support for Levi's treatment hierarchy (steroids first-line, benzodiazepines second, sulthiame + surgery as further options) that was previously referenced via the Kotagal 2017 review.
  • The 81% corticosteroid response rate quantitatively supports the decision to run the March 2026 IV methylprednisolone pulse early rather than trialing additional ASMs first.
  • The explicit avoid-oxcarbazepine/carbamazepine signal should be flagged on Levi's medication list and confirmed communicated to Stanford and UCSF epileptology.
  • Reinforces the Frontiers 2024 and Hempel 2019 findings that steroid courses can require re-dosing; the 81% response rate is for the initial response, not durability.

Citation note

Referenced as [13] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report. This is the primary source; 2017-kotagal-csws-treatment-review.md already in the corpus is a secondary review that cites this paper.